Exploring Innovative Immunological Solutions for Biological Problems
Dr. Shairaz baksh
Founder and President
Picture by Claudine Lavoie Photography
BioImmuno Designs, Inc. was created by Dr. Shairaz Baksh, a former Associate Professor at the University of Alberta in Edmonton, AB, Canada. We are a company dedicated to exploring the therapeutic potential of small molecules directed against inflammatory activators.
BioImmuno Designs, Inc. was created by Dr. Shairaz Baksh, a former Associate Professor at the University of Alberta in Edmonton, AB, Canada. We are a company dedicated to exploring the therapeutic potential of small molecules directed against inflammatory activators.
|
MISSION
To develop diagnostic tools for immunological disorders
To optimize the potential of small molecule therapeutics against hyperactive elements in the NFκB signaling family To create antibody replacement technologies to avoid the use of expensive and/or non-specific antibodies To uncover commonalities in inflammation driven diseases The NOD2/RIPK2 pathway has been demonstrated to be associated with all of the diseases on the right either directly or indirectly |
VISION
Our vision is to develop therapeutic approaches for diseases that have high unmet clinical need in addressable populations
To develop pathway-directed therapeutics to: 1. inflammatory bowel disease [IBD, Crohn's Disease (CD) and ulcerative colitis (UC) among other less prominent sub-types] 2. inflammation driven cancers (pancreatic cancer, Hodgkin’s Lymphoma, inflammatory breast cancer) and 3. Diseases with neuroinflammation and/or neuropathic pain (Stroke, Parkinson's Disease, Alzheimer's Disease, multiple sclerosis, other chronic diseases) 4. Other inflammatory diseases (such as osteoarthritis, sarcoidosis, pancreatitis, cystic fibrosis) |
APPROACH
Focus on inflammation and metabolic pathways driving inflammatory diseases
Use molecular modeling (docking) and chemoinformatics analyses to identify small molecule inhibitors to these common drivers Pre-clinical animal testing analyses to explore resolving inflammation in the major tissues (such as the colon, lung, pancreas and brain) Track ability to inhibit NFκB in vitro/in vivo and reverse the secondary (and tertiary) effects of acute and chronic inflammation using 3D organoid models |
